邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

丙酮酸激酶M2在胃癌中的作用

高洋,  孙昭,  白春梅

downloadPDF
文章导航 > 协和医学杂志  > 2021 >  12(2): 227-231
高洋, 孙昭, 白春梅. 丙酮酸激酶M2在胃癌中的作用[J]. 协和医学杂志, 2021, 12(2): 227-231. doi: 10.12290/xhyxzz.20190274
引用本文: 高洋, 孙昭, 白春梅. 丙酮酸激酶M2在胃癌中的作用[J]. 协和医学杂志, 2021, 12(2): 227-231. doi: 10.12290/xhyxzz.20190274
shu
GAO Yang, SUN Zhao, BAI Chun-mei. The Role of Pyruvate Kinase M2 in Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 227-231. doi: 10.12290/xhyxzz.20190274
Citation: GAO Yang, SUN Zhao, BAI Chun-mei. The Role of Pyruvate Kinase M2 in Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 227-231. doi: 10.12290/xhyxzz.20190274
shu

丙酮酸激酶M2在胃癌中的作用

doi: 10.12290/xhyxzz.20190274

  • 中国医学科学院 北京协和医学院 北京协和医院肿瘤内科，北京 100730

详细信息
    通讯作者:

    孙昭  电话：010-69158754, E-mail: jessiesz@126.com

  • 中图分类号: R735.2; R730.2

The Role of Pyruvate Kinase M2 in Gastric Cancer

  • Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
    Corresponding author: SUN Zhao   Tel: 86-10-69158754, E-mail: jessiesz@126.com

    摘要
  • 摘要: 胃癌是最常见的恶性肿瘤之一，其发病率与死亡率均呈较高水平。丙酮酸激酶M2(pyruvate kinase M2, PKM2)是糖酵解过程的关键限速酶，在多种肿瘤组织中表达明显升高，目前认为PKM2与肿瘤的发生、发展密切相关。在胃癌中，PKM2通过参与调节糖酵解途径、介导PI3K/Akt/mTOR信号通路活化、调控基因转录与细胞凋亡，进而促进胃癌细胞的增殖、转移，抑制细胞凋亡，最终加速胃癌的发展，本文将对此进行详细综述。
    Abstract: Gastric cancer is one of the most common malignant neoplasms with high morbidity and mortality. Pyruvate kinase M2 (PKM2) is one of the key rate-limiting enzymes in glycolysis. The expression of PKM2 is significantly increased in a variety of tumors. It is currently considered that PKM2 is related to the development of tumors. PKM2 may promote the development of gastric cancer through the regulation of glycolysis, activation of PI3K/Akt/mTOR and inhibition of apoptosis of tumor cells. Literature will be briefly summarized in this review.
    作者贡献：高洋负责文献查阅及文章撰写；孙昭、白春梅负责文章修订。
    利益冲突：  无
    • HTML全文
    • 参考文献(40)
  • [1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424. doi:  10.3322/caac.21492
    [2] Warburg O, Wind F, Negelein E. The metabolism of tumors in the body[J]. J Gen Physiol, 1927, 8: 519-530. doi:  10.1085/jgp.8.6.519
    [3] Burk D, Schade AL. On respiratory impairment in cancer cells[J]. Science, 1956, 124: 270-272. http://www.cell.com/servlet/linkout?suffix=e_1_5_1_2_150_2&dbid=8&doi=10.1016/j.tem.2013.03.002&key=13351639&cf=
    [4] Orang AV, Petersen J, McKinnon RA, et al. Micromanag-ing aerobic respiration and glycolysis in cancer cells[J]. Mol Metab, 2019, 23: 98-126. doi:  10.1016/j.molmet.2019.01.014
    [5] Rihan M, Nalla LV, Dharavath A, et al. Pyruvate kinase m2: A metabolic bug in Re-Wiring the tumor microenvironment[J]. Cancer Microenviron, 2019, 12: 149-167. doi:  10.1007/s12307-019-00226-0
    [6] Dong GC, Mao QX, Xia WJ, et al. PKM2 and cancer: The function of PKM2 beyond glycolysis[J]. Oncol Lett, 2016, 11: 1980-1986. doi:  10.3892/ol.2016.4168
    [7] Shiroki T, Yokoyama M, Tanuma N, et al. Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism[J]. Cancer Sci, 2017, 108: 931-940. doi:  10.1111/cas.13211
    [8] Hasan D, Gamen E, Abu Tarboush N, et al. PKM2 and HIF-1alpha regulation in prostate cancer cell lines[J]. PLoS One, 2018, 13: e203745. http://www.researchgate.net/publication/327657345_PKM2_and_HIF-1a_regulation_in_prostate_cancer_cell_lines
    [9] Méndez-Lucas A, Li XL, Hu JJ, et al. Glucose catabolism in liver tumors induced by c-MYC can be sustained by various PKM1/PKM2 ratios and pyruvate kinase activities[J]. Cancer Res, 2017, 77: 4355-4364. doi:  10.1158/0008-5472.CAN-17-0498
    [10] Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth[J]. Nature, 2008, 452: 230-233. doi:  10.1038/nature06734
    [11] Wong N, Ojo D, Yan J, et al. PKM2 contributes to cancer metabolism[J]. Cancer Lett, 2015, 356: 184-191. doi:  10.1016/j.canlet.2014.01.031
    [12] Chen S, Fisher RC, Signs S, et al. Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis[J]. Oncotarget, 2016, 8: 50476-50488. http://www.ncbi.nlm.nih.gov/pubmed/27286264
    [13] Ying J, Xu Q, Liu BX, et al. The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis[J]. Onco Targets Ther, 2015, 8: 2427-2433. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562727/
    [14] Wei L, Li K, Pang X, et al. Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2[J]. J Exp Clin Cancer Res, 2016, 35: 166. doi:  10.1186/s13046-016-0446-4
    [15] Hsu MC, Hung WC. Pyruvate kinase M2 fuels multiple aspects of cancer cells: From cellular metabolism, transcriptional regulation to extracellular signaling[J]. Mol Cancer, 2018, 17: 35. doi:  10.1186/s12943-018-0791-3
    [16] Mukherjee J, Ohba S, See WL, et al. PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells[J]. Int J Cancer, 2016, 139: 99-111. doi:  10.1002/ijc.30041
    [17] Yang WW, Xia Y, Ji HT, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation[J]. Nature, 2017, 480: 118-122. http://europepmc.org/articles/PMC3235705
    [18] Gao XL, Wang HZ, Yang JJ, et al. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase[J]. Mol Cell, 2012, 45: 598-609. doi:  10.1016/j.molcel.2012.01.001
    [19] Luo WB, Hu HX, Chang R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1[J]. Cell, 2011, 145: 732-744. doi:  10.1016/j.cell.2011.03.054
    [20] Luo WB, Semenza GL. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells[J]. Oncotarget, 2011, 2: 551-556. doi:  10.18632/oncotarget.299
    [21] Yang YC, Chien MH, Liu HY, et al. Nuclear translocation of PKM2/AMPK complex sustains cancer stem cell populations under glucose restriction stress[J]. Cancer Lett, 2018, 421: 28-40. doi:  10.1016/j.canlet.2018.01.075
    [22] Liang J, Cao RX, Wang XJ, et al. Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2[J]. Cell Res, 2017, 27: 329-351. doi:  10.1038/cr.2016.159
    [23] Li J, Yang Z, Zou Q, et al. PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer[J]. Clin Transl Oncol, 2014, 16: 200-207. doi:  10.1007/s12094-013-1063-8
    [24] Zhan C, Shi Y, Lu C, et al. Pyruvate kinase M2 is highly correlated with the differentiation and the prognosis of esophageal squamous cell cancer[J]. Dis Esophagus, 2013, 26: 746-753. http://smartsearch.nstl.gov.cn/paper_detail.html?id=42c237bc7ce4dcbb8fba3c3b0efdf8a8
    [25] Feng C, Gao Y, Wang CF, et al. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2013, 98: E1524-E1533. doi:  10.1210/jc.2012-4258
    [26] Wang C, Jiang JL, Ji J, et al. PKM2 promotes cell migra-tion and inhibits autophagy by mediating PI3K/AKT activation and contributes to the malignant development of gastric cancer[J]. Sci Rep, 2017, 7: 2886. doi:  10.1038/s41598-017-03031-1
    [27] Li H, Xu HY, Xing R, et al. Pyruvate kinase M2 contri-butes to cell growth in gastric cancer via aerobic glycolysis[J]. Pathol Res Pract, 2019, 215: 152409. doi:  10.1016/j.prp.2019.04.001
    [28] Wu JY, Hu L, Chen MY, et al. Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: Evidence from 16 cohort studies[J]. Onco Targets Ther, 2016, 9: 4277-4288. doi:  10.2147/OTT.S106508
    [29] Gao YS, Xu DY, Yu GZ, et al. Overexpression of metabolic markers HK1 and PKM2 contributes to lymphatic metastasis and adverse prognosis in Chinese gastric cancer[J]. Int J Clin Exp Pathol, 2015, 8: 9264-9271. http://old.med.wanfangdata.com.cn/viewHTMLEn/PeriodicalPaper_PM26464675.aspx
    [30] Lim JY, Yoon SO, Seol SY, et al. Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer[J]. World J Gastroenterol, 2012, 18: 4037-4043. doi:  10.3748/wjg.v18.i30.4037
    [31] Kato Y, Yashiro M, Noda S, et al. Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma[J]. Br J Cancer, 2010, 102: 898-907. doi:  10.1038/sj.bjc.6605543
    [32] Kitayama K, Yashiro M, Morisaki T, et al. Pyruvate kinase isozyme M2 and glutaminase might be promising molecular targets for the treatment of gastric cancer[J]. Cancer Sci, 2017, 108: 2462-2469. doi:  10.1111/cas.13421
    [33] Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics[J]. Oncogene, 2010, 29: 625-634. doi:  10.1038/onc.2009.441
    [34] Melillo G. Targeting hypoxia cell signaling for cancer therapy[J]. Cancer Metastasis Rev, 2007, 26: 341-352. doi:  10.1007/s10555-007-9059-x
    [35] Chen GX, Feng W, Zhang S, et al. Metformin inhibits gastric cancer via the inhibition of HIF1alpha/PKM2 signal-ing[J]. Am J Cancer Res, 2015, 5: 1423-1434. http://europepmc.org/articles/PMC4473320
    [36] Gao SM, Chen M, Wei W, et al. Crosstalk of mTOR/PKM2 and STAT3/c-Myc signaling pathways regulate the energy metabolism and acidic microenvironment of gastric cancer[J]. J Cell Biochem, 2018. doi: 10.1002/jcb.26915. Epub ahead of print.
    [37] Lu J, Chen M, Gao SM, et al. LY294002 inhibits the Warburg effect in gastric cancer cells by downregulating pyruvate kinase M2[J]. Oncol Lett, 2018, 15: 4358-4364. http://europepmc.org/abstract/MED/29541204
    [38] Wu HL, Medeiros LJ, Young KH. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances[J]. Blood Rev, 2018, 32: 8-28. doi:  10.1016/j.blre.2017.08.004
    [39] Pistritto G, Trisciuoglio D, Ceci C, et al. Apoptosis as anticancer mechanism: Function and dysfunction of its modula-tors and targeted therapeutic strategies[J]. Aging (Albany NY), 2016, 8: 603-619. http://pubmedcentralcanada.ca/pmcc/articles/PMC4925817/
    [40] Kwon OH, Kang TW, Kim JH, et al. Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level[J]. Biochem Biophys Res Commun, 2012, 423: 38-44. doi:  10.1016/j.bbrc.2012.05.063
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  49
  • HTML全文浏览量:  1
  • PDF下载量:  19
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-12-09
  • 录用日期:  2020-08-20
  • 网络出版日期:  2020-12-30
  • 刊出日期:  2021-05-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计